TransCode Therapeutics, Inc.
RNAZ
$6.97
-$0.235-3.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -263.27% | -44.73% | 56.20% | -19.56% | 30.93% |
| Total Depreciation and Amortization | -63.84% | -12.34% | -8.14% | 3.78% | 41.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,027.02% | 449.27% | -47.87% | 551.62% | 15.37% |
| Change in Net Operating Assets | 51.34% | 146.50% | -252.26% | 530.90% | -2,206.31% |
| Cash from Operations | 21.35% | 44.45% | -11.60% | 46.72% | 12.77% |
| Capital Expenditure | -- | -- | -180.43% | 74.59% | 70.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -180.43% | 74.59% | 70.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.47% | 623.98% | -66.27% | -87.91% | 415.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.47% | 623.98% | -66.89% | -87.65% | 415.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.31% | 183.99% | -138.11% | -179.96% | 164.14% |